GlassScriptPhysician profile
David M Stopperich
NPI 1265410906
$3,716.20
in general payments reported to CMS, 2019-2025
24 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $560 · 2021: $577 · 2022: $501 · 2023: $644 · 2024: $595 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.26 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $749.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $282.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $279.94 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $202.97 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $182.14 | 2019-2024 | |
| Allergan, INC. | $174.23 | 2019-2020 | |
| Exact Sciences Corporation | $164.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $135.72 | 2022-2024 | Rexulti |
| Eisai INC. | $103.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.13 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $88.68 | 2019-2024 | Jornay Pm |
| Astellas Pharma US INC | $76.70 | 2020-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $57.65 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $52.84 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $49.67 | 2022 | |
| Lilly USA, LLC | $47.64 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $47.59 | 2021 | |
| Corium, LLC | $28.74 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $28.61 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $28.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.53 | 2022 | |
| Mylan Specialty L.P. | $15.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.06 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stopperich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.